ライフサイエンスコーパス: rhDNase

1 rhDNase therapy is safe and well tolerated in CF patient

2 that recombinant human deoxyribonuclease 1 (rhDNase) reduces airflow obstruction and improves mucoci

3 may justify a clinical trial of aerosolized rhDNase in this population.

4 Our results indicate that aerosolized rhDNase improves FEV1 and FVC independent of CPT.

5 that improvements seen in FEV1 and FVC after rhDNase treatment are independent of chest physical ther

6 improved lung function to the same degree as rhDNase in short-term studies.

7 e imaging revealed that PEG30 kDa-conjugated rhDNase (PEG30-rhDNase) was retained in mouse lungs for

8 jet nebuliser, is not as effective as daily rhDNase, although there is variation in individual respo

9 (95% CI -546 to 1510) and that between daily rhDNase and hypertonic saline was pound1409 (440 to 2318

10 However, daily rhDNase showed a significantly greater increase in FEV(1

11 We compared the effectiveness of daily rhDNase, hypertonic saline, and alternate-day rhDNase in

12 ed in random order to 12 weeks of once-daily rhDNase (2.5 mg), alternate-day rhDNase (2.5 mg), and tw

13 in mediator levels from baseline with daily rhDNase and HS was not significant; however, with altern

14 When changes in mediator levels with daily rhDNase were compared with alternate-day rhDNase and HS,

15 (SD 25%), 14% (22%), and 3% (21%) with daily rhDNase, alternate-day rhDNase, and hypertonic saline, r

16 o difference between daily and alternate-day rhDNase (2% [95% CI -4 to 9], p=0.55).

17 f once-daily rhDNase (2.5 mg), alternate-day rhDNase (2.5 mg), and twice-daily 5 mL 7% hypertonic sal

18 ily rhDNase were compared with alternate-day rhDNase and HS, no significant differences were detected

19 hDNase, hypertonic saline, and alternate-day rhDNase in children with cystic fibrosis.

20 12-week cost between daily and alternate-day rhDNase was pound513 (95% CI -546 to 1510) and that betw

21 d 3% (21%) with daily rhDNase, alternate-day rhDNase, and hypertonic saline, respectively.

22 not significant; however, with alternate-day rhDNase, there was an increase in free IL-8.

23 a difference between daily and alternate-day rhDNase.

24 Daily recombinant human deoxyribonuclease (rhDNase) is an established but expensive treatment in cy

25 ety and efficacy of recombinant human DNase (rhDNase) in hospitalized patients with cystic fibrosis (

26 Recombinant human DNase (rhDNase) is an established treatment in cystic fibrosis

27 on of recombinant human deoxyribonuclease I (rhDNase) to polyethylene glycol (PEG) of 20 to 40 kDa wa

28 cord barrier permeability was attenuated in rhDNase-treated animals.

29 rung walking test, was improved at 35 dpi in rhDNase-treated animals compared to vehicle-treated cont

30 accumulated data on the glycation process in rhDNase I, formulated with lactose and stored in the dry

31 Systemic absorption of intact rhDNase and PEG30-rhDNase was observed.

32 nsecutively to 12 weeks of once-daily 2.5 mg rhDNase, alternate-day 2.5 mg rhDNase, and twice-daily 7

33 e-daily 2.5 mg rhDNase, alternate-day 2.5 mg rhDNase, and twice-daily 7% HS.

34 nificantly longer period of time than native rhDNase (12 days vs 5 days).

35 Administration of rhDNase was not associated with acute adverse events or

36 We compared the effect of rhDNase and HS on cationic proinflammatory mediators in

37 tistically significant therapeutic effect of rhDNase when added to a regimen of antibiotics and chest

38 ether, our data demonstrate the potential of rhDNase as an anti-ET therapeutic to improve long-term S

39 ously shown to prolong the residence time of rhDNase in the lungs of mice after pulmonary delivery wh

40 s on long-term aerosolized tobramycin and/or rhDNase had worse baseline lung function, but still bene

41 temic absorption of intact rhDNase and PEG30-rhDNase was observed.

42 led that PEG30 kDa-conjugated rhDNase (PEG30-rhDNase) was retained in mouse lungs for a significantly

43 ed to study the fate of native and PEGylated rhDNase in the lungs and to elucidate their biodistribut

44 ation pathways for both native and PEGylated rhDNase.

45 The prolonged presence of PEGylated rhDNase in lung airspaces appears ideal for its mucolyti

46 croscopy confirmed the presence of PEGylated rhDNase in lung airspaces for at least 7 days.

47 Patients were randomized to receive rhDNase 2.5 mg in 2.5 ml excipient twice a day (n = 43)

48 We were unable to demonstrate that rhDNase reduces airflow obstruction or improves mucocili

49 In summary, we were unable to show that rhDNase or HS promote airway inflammation in CF.

50 ompared with baseline (0.70 +/- 0.05) in the rhDNase group.

51 EV1 and FVC were significantly higher in the rhDNase-treated group than in the placebo group, increas

52 In contrast, the unconjugated rhDNase was cleared from the lung lumina within 24 h and

53 Here, we used rhDNase, which only forms His-His covalent dimers after

54 When rhDNase was administered at 1 hpi, DNase activity in the